NCT05465876View on ClinicalTrials.gov

Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2025

Conditions
Chronic Lymphocytic LeukemiaCOVID-19
Interventions
BIOLOGICAL

EVUSHELD

EVUSHELD is a combination of 2 monoclonal antibodies (mAbs), Tixagevimab and Cilgavimab. The single dose, is to be administered intramuscular, each mAb sequentially into the deltoid

Trial Locations (1)

M4N 3M5

Sunnybrook Health Sciences Cente, Toronto

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Sunnybrook Health Sciences Centre

OTHER